云南白药 - Financials

云南白药 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	40.0B	39.1B	36.5B	36.4B	32.7B
Revenue Growth %	2.4%	7.2%	0.3%	11.1%	--
Total Revenue	40.0B	39.1B	36.5B	36.4B	32.7B
Cost Of Revenue	28.9B	28.7B	26.9B	26.5B	23.7B
+Gross Profit	11.2B	10.4B	9.6B	9.9B	9.1B
Gross Margin %	27.9%	26.5%	26.3%	27.2%	27.8%
Total Operating Cost	35.3B	35.3B	33.5B	32.2B	28.8B
Selling Expenses	4.9B	5.0B	4.2B	3.9B	3.8B
Admin Expenses	1.0B	1.1B	834.0M	1.1B	860.0M
Rd Expenses	337.0M	336.0M	337.0M	331.0M	181.0M
Finance Expenses	-156.0M	-259.0M	-343.0M	-258.0M	-232.0M
+Operating Income	5.7B	4.8B	3.4B	3.5B	6.8B
Operating Margin %	14.3%	12.4%	9.2%	9.6%	20.8%
Non Operating Income	15.5M	12.2M	13.6M	10.1M	8.4M
Non Operating Expenses	42.4M	24.7M	7.9M	13.7M	19.3M
Investment Income	777.0M	779.0M	868.0M	1.0B	392.0M
Fair Value Change Income	137.0M	124.0M	-620.0M	-1.9B	2.2B
Asset Disposal Income	490,700	10.7M	5.9M	4.5M	14.2M
Asset Impairment Loss	91.2M	58.1M	664.0M	143.0M	125.0M
Other Income	102.0M	83.3M	105.0M	149.0M	179.0M
Income Before Tax	5.7B	4.8B	3.4B	3.5B	6.8B
Income Tax	918.0M	695.0M	537.0M	684.0M	1.3B
+Net Income	4.8B	4.1B	2.8B	2.8B	5.5B
Net Margin %	11.9%	10.5%	7.8%	7.7%	16.8%
Net Income Attributable	4.7B	4.1B	3.0B	2.8B	5.5B
Minority Interest	17.7M	28.8M	-161.0M	-7.3M	-5.0M
Eps Basic	2.66	2.29	1.90	2.21	4.32
Eps Diluted	2.66	2.29	1.90	2.18	4.31

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	10.9B	14.2B	13.1B	18.9B	15.3B
Trading Financial Assets	2.5B	149.0M	2.4B	4.7B	11.2B
Accounts Receivable	9.9B	10.0B	9.1B	7.2B	3.6B
Notes Receivable	930.0M	228.0M	789.0M	328.0M	3.0B
Notes And Accounts Receivable	10.9B	10.2B	9.9B	7.5B	6.6B
Prepayments	304.0M	312.0M	543.0M	531.0M	465.0M
Inventory	6.3B	6.4B	8.0B	8.4B	11.0B
Total Current Assets	34.2B	36.3B	35.7B	45.5B	49.3B
Long Term Equity Investment	12.6B	11.5B	11.3B	185.0M	329.0M
Fixed Assets	--	2.7B	2.7B	3.0B	3.1B
Fixed Assets Total	3.0B	2.7B	2.7B	3.0B	3.1B
Construction In Progress	--	530.0M	194.0M	230.0M	387.0M
Construction In Progress Total	703.0M	530.0M	194.0M	230.0M	387.0M
Intangible Assets	562.0M	583.0M	591.0M	699.0M	535.0M
Long Term Deferred Expenses	127.0M	105.0M	103.0M	25.5M	36.1M
Total Non Current Assets	18.8B	17.5B	17.6B	6.8B	6.0B
Total Assets	52.9B	53.8B	53.3B	52.3B	55.2B
Short Term Borrowings	423.0M	1.7B	1.9B	1.7B	2.0B
Accounts Payable	4.8B	4.4B	4.6B	4.2B	4.6B
Advance Receipts	446,700	486,600	1.6M	1.4M	1.9M
Contract Liabilities	1.9B	1.7B	2.6B	2.4B	2.1B
Total Current Liabilities	12.9B	12.7B	13.6B	12.7B	15.6B
Long Term Borrowings	2.1M	2.1M	2.1M	89.6M	36.6M
Total Non Current Liabilities	1.2B	1.1B	1.2B	1.2B	1.2B
Total Liabilities	14.0B	13.9B	14.8B	13.9B	16.9B
Paid In Capital	1.8B	1.8B	1.8B	1.3B	1.3B
Capital Reserve	17.6B	18.2B	18.2B	18.1B	17.7B
Surplus Reserve	2.5B	2.5B	2.5B	2.5B	2.1B
Retained Earnings	17.0B	18.1B	16.7B	16.3B	18.8B
Minority Equity	34.1M	26.2M	23.3M	208.0M	291.0M
Equity Attributable	38.8B	39.9B	38.5B	38.2B	38.1B
Total Equity	38.9B	39.9B	38.5B	38.4B	38.3B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	43.3B	40.6B	38.2B	39.6B	35.2B
Tax Refunds Received	13.5M	4.9M	159.0M	11.7M	23.9M
Total Operating Cash Inflow	43.9B	41.3B	39.1B	40.4B	35.8B
Cash Paid For Goods	31.3B	29.8B	28.7B	27.1B	25.5B
Cash Paid To Employees	2.8B	2.6B	2.3B	2.1B	1.5B
Taxes Paid	2.5B	2.5B	2.3B	2.6B	2.0B
Total Operating Cash Outflow	39.6B	37.8B	35.9B	35.2B	32.0B
Operating Cash Flow	4.3B	3.5B	3.2B	5.2B	3.8B
Total Investing Cash Inflow	8.0B	5.0B	6.8B	10.9B	29.2B
Total Investing Cash Outflow	9.2B	4.5B	13.2B	6.9B	28.1B
Investing Cash Flow	-1.2B	519.0M	-6.3B	4.0B	1.1B
Cash From Borrowings	1.9B	1.4B	2.3B	1.7B	2.0B
Dividends And Interest Paid	6.0B	2.8B	2.1B	5.0B	3.9B
Debt Repayments	2.8B	1.4B	2.2B	2.7B	22.0M
Total Financing Cash Inflow	2.0B	1.4B	2.4B	3.2B	2.8B
Total Financing Cash Outflow	8.9B	4.3B	5.2B	7.8B	5.8B
Financing Cash Flow	-7.0B	-2.9B	-2.7B	-4.6B	-3.0B
Net Change In Cash	-3.9B	1.1B	-5.8B	4.6B	1.9B
Ending Cash Balance	10.3B	14.2B	13.0B	18.9B	14.3B
Capex	675.0M	576.0M	447.0M	534.0M	486.0M